WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562589
CAS#: 622855-50-9
Description: Wee1 Inhibitor II is an ATP-binding site-targeting inhibitor of Wee1.
Hodoodo Cat#: H562589
Name: Wee1 Inhibitor II
CAS#: 622855-50-9
Chemical Formula: C24H19ClN2O3
Exact Mass: 418.11
Molecular Weight: 418.870
Elemental Analysis: C, 68.82; H, 4.57; Cl, 8.46; N, 6.69; O, 11.46
Synonym: Wee1 Inhibitor II; Wee1 Inhibitor-II; Wee1-Inhibitor-II; Wee1-Inhibitor II;
IUPAC/Chemical Name: 6-Butyl-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione
InChi Key: HLSZACLAFZWCCS-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H19ClN2O3/c1-2-3-10-27-18-9-8-13(28)11-16(18)20-19(27)12-15(14-6-4-5-7-17(14)25)21-22(20)24(30)26-23(21)29/h4-9,11-12,28H,2-3,10H2,1H3,(H,26,29,30)
SMILES Code: O=C1NC(C2=C1C3=C(C=C2C4=CC=CC=C4Cl)N(CCCC)C5=C3C=C(O)C=C5)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 418.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Visconti R, Grieco D. Fighting tubulin-targeting anticancer drug toxicity and resistance. Endocr Relat Cancer. 2017 Sep;24(9):T107-T117. doi: 10.1530/ERC-17-0120. Review. PubMed PMID: 28808045.
2: Tamura K. Development of cell-cycle checkpoint therapy for solid tumors. Jpn J Clin Oncol. 2015 Dec;45(12):1097-102. doi: 10.1093/jjco/hyv131. Epub 2015 Oct 20. Review. PubMed PMID: 26486823.
3: Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci. 2001 Nov;58(12-13):1907-22. Review. PubMed PMID: 11766887.
4: Maller JL, Gross SD, Schwab MS, Finkielstein CV, Taieb FE, Qian YW. Cell cycle transitions in early Xenopus development. Novartis Found Symp. 2001;237:58-73; discussion 73-8. Review. PubMed PMID: 11444050.